Gilead and Glympse Bio Announce Strategic Collaboration for Use of Biomarker Technology in NASH Clinical Development
Gilead Sciences Inc. (Nasdaq: GILD) and Glympse Bio, Inc., today announced that the companies have entered into a strategic collaboration in nonalcoholic steatohepatitis (NASH) clinical development. Glympse Bio’s proprietary synthetic biomarkers – bioengineered to identify stage and progression of disease as well as early detection of treatment response – will be used to determine clinical trial participants’ stage of disease at initial screening and to determine responses to study treatment in Gilead’s NASH clinical program.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191028005145/en/
“We are excited about the opportunity to partner with Glympse Bio to help inform our NASH development program,” said Mani Subramanian, MD, PhD Senior Vice President, Liver Diseases, Gilead Sciences. “By utilizing this innovative technology, we hope to better characterize this complex disease and improve our understanding of how our compounds impact disease progression.”
Glympse Bio’s proprietary technology, Glympse Inside™, combines synthetic biomarkers with machine learning approaches to identify the stage and monitor progression of important, complex diseases such as cancer, fibrosis, inflammation, and infections, in real time.
“We are very excited about partnering with Gilead, a leader in drug development, to help drive earlier and more favorable outcomes for patients,” said Caroline J Loew, President and CEO, Glympse Bio. “Gilead’s commitment to developing innovative medicines in areas of high unmet medical need aligns with our mission of transforming disease detection and measuring treatment response, all with the goal of helping improve the lives of patients.”
Financial terms of the agreement were not disclosed.
About Glympse Bio
Glympse Bio is pioneering the development of disruptive, non-invasive technology to directly query disease activity inside the body. The Company’s proprietary synthetic biomarkers – biological sensors developed using breakthroughs in science, engineering, medicine and artificial intelligence – are potentially tunable to a multitude of diseases and offer earlier measures of response to disease and treatment. By integrating real-time biological activity with sophisticated machine learning and artificial intelligence, Glympse Inside™ is a pan-disease product engine that aims to transform disease monitoring and treatment response. The company is based at the Lab Central incubator in Cambridge, MA. For more information, please visit http://www.glympsebio.com.
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
Gilead Forward-Looking Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the risk that the parties may not realize the potential benefits of this collaboration. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2019, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191028005145/en/
Contact information
Sung Lee, Investors
(650) 524-7792
Beth Kurth
(617) 584-9650
bkurth@conwaycommsir.com
Arran Attridge, Media
(650) 425-8975
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mori Memorial Foundation’s Global Power City Index 2025 Sees City Rankings Shift Due to Tourism Gains in East Asia and Inflationary Pressures in the West17.12.2025 05:00:00 EET | Press release
The Mori Memorial Foundation’s Institute for Urban Strategies, a research body established by Mori Building, Tokyo’s leading urban landscape developer, today published its annual Global Power City Index (GPCI) 2025, a report evaluating the urban competitiveness of 48 major cities worldwide. The report also includes the GPCI–Financial Centers index, an assessment of cities as international financial centers, and the new GPCI–Startup Ecosystems index, which assesses the competitiveness of startup environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216187692/en/ 48 Major Cities Evaluated in Mori Memorial Foundation’s GPCI-2025 Report This year’s report highlights the remarkable rise of East Asian cities and the stagnation of several Western cities, showing how global challenges, such as geopolitical tensions and regional disparities in inflation, are greatly impacting the performance of major cities worldwide. The r
GE HealthCare and Indonesia’s Ministry of Health to expand access to quality care through the provision of 300+ advanced CT scanners17.12.2025 04:00:00 EET | Press release
GE HealthCare (Nasdaq: GEHC) today announced it will supply more than 300 CT (computed tomography) scanners under Indonesia’s Strengthening Indonesia’s Health Referral Network (SIHREN) program to deliver equitable, high-quality care to more than 280 million Indonesians. As part of a competitively awarded, multi-year contract, GE HealthCare will supply the advanced CT scanners to public hospitals across all 38 provinces, including urban and remote areas. The CT scanner procurement under SIHREN was conducted through a fully competitive international tender process governed by the World Bank’s procurement regulations. SIHREN is the largest healthcare infrastructure investment in Indonesia’s history and among the largest multilateral health projects globally. SIHREN aims to modernize the national referral system and expand access to diagnostics and treatment across the archipelago, with a focus on non-communicable diseases (NCD) management, maternal health, and pandemic resilience. By mode
IDWS 2025 Concludes with Focus on Global Knowledge Exchange, Financial Opportunities, and Scalable Water Solutions16.12.2025 21:03:00 EET | Press release
The 4th Innovation Driven Water Sustainability Conference (IDWS) 2025 concluded on Wednesday in Jeddah, confirming its status as one of the world’s most influential platforms for shaping the future of water innovation, sustainability, and security. Gathering senior global policymakers and international industry leaders, this year’s edition has advanced critical dialogue on safeguarding the planet’s most vital resource, with Saudi Arabia at the forefront. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216483490/en/ Investors, innovators, and global institutions gather in Saudi to outline how capital, collaboration, and governance can accelerate long term water sustainability (Photo: AETOSWire) Among the most consequential engagements were a series of meetings that brought together discussions powered by SWA, centred on shared challenges, knowledge exchange, and exploring opportunities within the global water ecosystem. Att
OAG Appoints ex-Skyscanner Executive Filip Filipov as New Chief Executive Officer16.12.2025 18:00:00 EET | Press release
OAG announces today the appointment of Filip Filipov, ex-Skyscanner executive, as new Chief Executive Officer. Filip Filipov currently serves as the company’s Chief Operating Officer and takes over from Phil Callow who has chosen to step down having completed thirteen transformational years at the helm of OAG to pursue his many other interests. Since joining in 2024, Filipovhas played a leading role in the company’s ambitious next phase of growth and ongoing acceleration. He will now lead OAG into a new era defined by advanced data products and AI-driven intelligence. Before joining OAG, Filipov held senior roles in travel technology and big-data consulting, including on Skyscanner’s executive team. Filip Filipov said: “It’s a privilege to step into this role and lead a company with such a strong heritage and reputation. I’m excited for what’s ahead and committed to serving our customers with the reliability, service, and innovation they depend on.” Chairman of OAG, Gehan Talwatte, com
Xsolla Integrates SPENN in Rwanda and Zambia Giving Developers Access to a Strong Consumer-Merchant Ecosystem16.12.2025 17:49:00 EET | Press release
Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their games, today announced that it has added SPENN to its payments solution portfolio in Rwanda and Zambia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216303338/en/ Xsolla Integrates SPENN In Rwanda And Zambia Giving Developers Access To A Strong Consumer-Merchant Ecosystem Both Rwanda and Zambia are mobile-first, wallet-led economies where mobile money drives financial inclusion and rapid growth in digital transactions. Reports found that approximately 86% of Rwandan adults own or have used mobile money. As of mid-2024, mobile money transaction volumes in Zambia increased by 44% to 1.4 billion transactions from mid-2023. By adding SPENN as a payment method to its portfolio, Xsolla enables players to continue paying seamlessly in a way they are already familiar with. Key benefits of the SPENN integration include: Streamline
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom